Stiripentol for ADHD Treatment Reducing Dependency Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for attention deficit hyperactivity disorder (ADHD) like methylphenidate have potential for drug dependency and long-term brain development changes, necessitating alternative therapeutic options.
Innovation Solution
The compound Stiripentol, structurally unrelated to other antiepileptic drugs, is found effective in reducing hyperactivity in a rat model of ADHD, and its use or its pharmaceutically acceptable salts are proposed for the prevention or treatment of ADHD, potentially in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylphenidate is used to treat ADHD, then hyperactivity and impulsivity are reduced, but drug dependency and long-term brain development changes occur
Solution Approach 1:
The patent applies parameter changes by introducing a new chemical compound (stiripentol) with different pharmacological properties than methylphenidate. Stiripentol is a broad-spectrum anticonvulsant that acts through GABAergic mechanisms, fundamentally changing the therapeutic parameter from dopamine reuptake inhibition to GABA enhancement, thereby maintaining effectiveness while eliminating dependency risks
Solution Approach 2:
The patent positions stiripentol as a temporary or alternative therapeutic option that can be used without long-term commitment concerns. As an anticonvulsant with a different mechanism of action, it serves as a short-term or alternative treatment that addresses hyperactivity without the cumulative harmful effects associated with prolonged methylphenidate use
2Object-affected harmful factors
If stiripentol is used to treat ADHD, then hyperactivity is reduced without drug dependency, but the mechanism of action differs from conventional ADHD treatments
Solution Approach 1:
The patent leverages the universality of stiripentol as a broad-spectrum anticonvulsant that can be repurposed for ADHD treatment. Its established safety profile and multi-functional use in epilepsy treatment provide a foundation for off-label ADHD application, reducing the need for extensive new safety studies while addressing the dependency issue
Solution Approach 2:
The patent uses GABA as an intermediary mechanism. Stiripentol enhances GABAergic transmission, which indirectly modulates dopamine and norepinephrine systems involved in ADHD pathology. This intermediary approach allows treatment of ADHD symptoms through a different neurochemical pathway, avoiding direct dopamine reuptake inhibition and its associated dependency risks
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of attention deficit and/or hyperactivity in an individual.